Five-Year Evaluation Coverage, 2025-26 to 2029-30
| Program | Title of Planned Evaluations | Planned Year of Approval | Estimated 2025-26 Program Spending Covered by Evaluation | Total 2025-26 Planned Program Spending |
|---|---|---|---|---|
Patented Medicine Price Monitoring Program |
No planned evaluation |
N/A |
N/A |
$12,285,557 |
Pharmaceutical Trends Program |
No planned evaluation |
N/A |
N/A |
$2,343,152 |
Internal Services |
No planned evaluation |
N/A |
N/A |
$3,500,223 |
Additional explanatory note: No planned evaluations to 2029-30 given transition from amendments to Patented Medicine Regulations and new Guidelines. The evaluation need will be reassessed each year.
Page details
- Date modified: